From the Research
Journay PM is not recommended for individuals with autism spectrum disorder (ASD) due to insufficient evidence supporting its use and potential risks. The medication combines dextromethorphan, which affects glutamate receptors, and bupropion, which inhibits the breakdown of dextromethorphan. While some research suggests glutamate modulation may benefit certain neurological conditions, there is currently insufficient evidence supporting Journay PM's use in autism 1, 2.
Key Considerations
- Patients with autism often have different medication needs focusing on specific symptoms like irritability, anxiety, or attention issues, which are typically addressed with FDA-approved medications such as risperidone, aripiprazole, or SSRIs.
- Journay PM carries risks including seizures and serotonin syndrome that could be particularly concerning for individuals with autism who may have comorbid seizure disorders or be taking other serotonergic medications.
- Any medication approach for autism should be part of a comprehensive treatment plan that includes behavioral therapies and educational interventions, with medication decisions made by healthcare providers experienced in autism care who can weigh potential benefits against risks for each individual.
Alternative Treatments
- Melatonin has been shown to be effective in improving sleep quality in individuals with ASD, with a recent meta-analysis demonstrating its positive effect on total sleep time, sleep latency, and sleep efficiency 3.
- Other medications such as α2-adrenergic agonists, buspirone, and mirtazapine may be preferred for treating ADHD, anxiety, and depression in ASD patients, respectively 4.
- Guanfacine, risperidone, or aripiprazole may be appropriate for addressing irritability in ASD, depending on severity 4.
Conclusion Not Applicable
Instead, the focus should be on prioritizing the single most recent and highest quality study, which in this case is the 2025 study on melatonin interventions in ASD 5. This study highlights the potential benefits of melatonin in regulating sleep and improving behavioral outcomes in individuals with ASD, and emphasizes the need for personalized and comprehensive treatment plans. Therefore, melatonin may be a valuable component in the treatment of ASD, particularly for sleep disturbances, and should be considered as part of a comprehensive treatment plan.